Send to

Choose Destination
Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):399-404.

[Immunotherapy using IL-6 receptor as the target].

[Article in Japanese]

Author information

Laboratory of Immune Regulation, Wakayama Medical University.

Erratum in

  • Nihon Rinsho Meneki Gakkai Kaishi. 2008 Dec;31(6):423.


Monoclonal antibody-based therapy targeting interleukine-6 (IL-6) has been established as a treatment for autoimmune diseases, chronic inflammatory diseases, and lymphoproliferative disease. IL-6 is a multifunctional cytokine which plays pathological roles in Castleman's disease, rheumatoid arthritis, juvenile idiopathic arthritis, and Crohn's disease. Many groups have been exploring the therapeutic approach to block the IL-6 signal, and tocilizumab, a humanized monoclonal antibody against human IL-6 receptor, has been the most intensively studied agent for clinical use. A series of clinical trials of tocilizumab have demonstrated the robustness of safety and efficacy of tocilizumab in the treatment of patients with above diseases. In this review, targeting IL-6 actions as an immunotherapy is discussed.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
Loading ...
Support Center